Multiply robust subgroup analysis based on a single-index threshold linear marginal model for longitudinal data with dropouts

Time-varying mediation analysis for incomplete data with application to DNA methylation study for PTSD

DNA methylation (DNAm) has been shown to mediate causal effects from traumatic experiences to post-traumatic stress disorder (PTSD). However, the scientific question about whether the mediation effect changes over time remains unclear. In this paper, we develop time-varying structural equation models to identify cytosine-phosphate-guanine (CpG) sites where DNAm mediates the effect of trauma exposure on PTSD, and to capture dynamic changes in mediation effects. The proposed methodology is motivated by the Detroit Neighborhood Health Study (DNHS) with high-dimensional and longitudinal DNAm measurements. To handle the non-monotone missing DNAm in the dataset, we propose a novel Longitudinal Multiple Imputation (LMI) method utilizing dependency among repeated measurements, and employ the generalized method of moments to integrate the multiple imputations. Simulations confirm that the proposed method outperforms existing approaches in various longitudinal settings. In DNHS data analysis, our method identifies several CpG sites where DNAm exhibits dynamic mediation effects. Some of the corresponding genes have been shown to be associated with PTSD in the existing literature, and our findings on their time-varying effects could deepen the understanding of the mediation role of DNAm on the causal path from trauma exposure to PTSD risk.

Regression analysis of longitudinal data with random change point

A great deal of literature has been established for regression analysis of longitudinal data and in particular, many methods have been proposed for the situation where there exist some change points. However, most of these methods only apply to continuous response and focus on the situations where the change point only occurs on the response or the trend of the individual trajectory. In this article, we propose a new joint modeling approach that allows not only the change point to vary for different subjects or be subject-specific but also the effect heterogeneity of the covariates before and after the change point. The method combines a generalized linear mixed effect model with a random change point for the longitudinal response and a log-linear regression model for the random change point. For inference, a maximum likelihood estimation procedure is developed and the asymptotic properties of the resulting estimators, which differ from the standard asymptotic results, are established. A simulation study is conducted and suggests that the proposed method works well for practical situations. An application to a set of real data on COVID-19 is provided.

Subgroup analysis for longitudinal data based on a partial linear varying coefficient model with a change plane

Subgroup analysis has become an important tool to characterize the treatment effect heterogeneity, and finally towards precision medicine. On the other hand, longitudinal study is widespread in many fields, but subgroup analysis for this data type is still limited. In this article, we study a partial linear varying coefficient model with a change plane, in which the subgroups are defined based on linear combination of grouping variables, and the time-varying effects in different subgroups are estimated to capture the dynamic association between predictors and response. The varying coefficients are approximated by basis functions and the group indicator function is smoothed by kernel function, which are included in the generalized estimating equation for estimation. Asymptotic properties of the estimators for the varying coefficients, the constant coefficients and the change plane coefficients are established. Simulations are conducted to demonstrate the flexibility, efficiency and robustness of the proposed method. Based on the Standard and New Antiepileptic Drugs study, we successfully identify a subgroup in which patients are sensitive to the newer drug in a specific period of time.